PMID-32257855 – Growth Hormone Secretagogues in Body Composition Management
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Jankovic J, Pastuszak AW, Bhatt DK, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
Quick Reference
| Property | Value |
|---|---|
| PMID | 32257855 |
| DOI | 10.21037/tau.2019.11.30 |
| Year | 2020 |
| Journal | Translational Andrology and Urology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of GH secretagogues for body composition in hypogonadal males |
| Peptide(s) Studied | Ipamorelin, CJC-1295 NO DAC |
Key Findings
- Clinical review positioning ipamorelin and other GH secretagogues as adjunctive therapies for body composition optimization in hypogonadal males
- Describes ipamorelin as a "potent GH and IGF-1 stimulator" with favorable selectivity profile
- Reviews the theoretical benefits of GH secretagogues for lean mass gain, fat loss, and metabolic improvement
- Acknowledges that clinical data supporting GH secretagogue use for body composition remains limited
- Discusses the mechanistic rationale for combining GH axis optimization with testosterone replacement therapy (TRT)
- Positions CJC-1295 + ipamorelin as the most commonly used GH secretagogue combination in clinical practice
Study Design
Narrative review of the published literature on GH secretagogues (including ipamorelin, GHRP-2, GHRP-6, CJC-1295, sermorelin, and MK-677) as they relate to body composition management in hypogonadal males. Evaluated mechanisms of action, available clinical evidence, safety profiles, and practical considerations for integration with testosterone therapy.
Limitations
- Narrative review with potential selection bias
- Limited high-quality clinical trial data available for most GH secretagogues reviewed
- Focus on hypogonadal males limits applicability to women and eugonadal populations
- No quantitative analysis of effect sizes across studies
- Some recommendations are based on clinical experience rather than evidence-based guidelines
- Potential conflicts of interest not fully disclosed
Clinical Relevance
This review from a urology/andrology journal is particularly relevant for practitioners who manage male patients on testosterone therapy and are considering GH axis optimization. It provides a clinical framework for integrating ipamorelin and CJC-1295 into existing hormone optimization protocols. The honest acknowledgment of limited clinical data is important for informed consent discussions. For the Ageless Peps practitioner audience, this review supports the rationale for protocols combining CJC-1295/ipamorelin (available as the AP blend product) with broader hormonal optimization strategies.
Related
#research #narrative-review #ipamorelin #CJC-1295 #evidence-level-V